A Phase 2/3, Randomized, Open-Label Study of Bempegaldesleukin Plus Pembrolizumab vs. Pembrolizumab Alone in First-Line Treatment of Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma with PD-L1-Expressing Tumors (PROPEL-36)

A Phase 2/3, Randomized, Open-Label Study of Bempegaldesleukin Plus Pembrolizumab vs. Pembrolizumab Alone in First-Line Treatment of Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma with PD-L1-Expressing Tumors (PROPEL-36) Article

Web of Science: 000769937700074

Industry Collaboration International Collaboration

Cited authors

Seiwert TY, Haddad RI, Johnson D, Gillison M, Keilholz U, Tahara M, Machiels JP, Deeken J, Villaflor V, Su Y, Guthrie T, Shin DM, De Block K, Meirovitz A, Chien D, Tagliaferri M, Zalvesky J, Harrington K

Authors

Johnson, Daniel, MD

Publication date

2022

Category

ONCOLOGY Category
RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Category

International Standard Serial Number (ISSN)

0360-3016

Number of pages

2

Start page

E36

End page

E37

Volume

112

Issue

5